Allay grants acute pain management drug license to Japan’s Maruishi Pharmaceutical
Allay Therapeutics has announced a licensing agreement granting Maruishi Pharmaceutical exclusive rights to develop and commercialise ATX101, a non-opioid upivacaine-based drug, and other ultra-sustained analgesic implantable drug candidates for acute pain, in Japan.